Sourav Santra

516 total citations
14 papers, 385 citations indexed

About

Sourav Santra is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Sourav Santra has authored 14 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 4 papers in Genetics and 4 papers in Oncology. Recurrent topics in Sourav Santra's work include Multiple Sclerosis Research Studies (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Acute Lymphoblastic Leukemia research (3 papers). Sourav Santra is often cited by papers focused on Multiple Sclerosis Research Studies (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Acute Lymphoblastic Leukemia research (3 papers). Sourav Santra collaborates with scholars based in United States, Germany and Austria. Sourav Santra's co-authors include H. Küpper, Josef S Smolen, Paul Emery, Arthur Kavanaugh, Laura Redden, B. Guérette, Roy Fleischmann, Christophe Hotermans, Lily Lee and Steven Galetta and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Annals of the Rheumatic Diseases.

In The Last Decade

Sourav Santra

14 papers receiving 374 citations

Peers

Countries citing papers authored by Sourav Santra

Since Specialization

Citations

This map shows the geographic impact of Sourav Santra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sourav Santra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sourav Santra more than expected).

Fields of papers citing papers by Sourav Santra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sourav Santra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sourav Santra. The network helps show where Sourav Santra may publish in the future.

Co-authorship network of co-authors of Sourav Santra

This figure shows the co-authorship network connecting the top 25 collaborators of Sourav Santra. A scholar is included among the top collaborators of Sourav Santra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sourav Santra. Sourav Santra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy 2023 ·Therapeutic Advances in Neurological Disorders ·(unknown), (unknown), Danielle A. Griffin, (unknown), (unknown), (unknown), (unknown), Sourav Santra, Damon R. Asher, Craig M. Zaidman	19
2	Evaluation of Total Binding Antibodies Against rAAVrh74 in Patients with Duchenne Muscular Dystrophy (P14-13.005) 2022 ·Neurology ·(unknown), (unknown), (unknown), Sourav Santra, (unknown), (unknown), Craig M. Zaidman	1
3	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment 2021 ·Journal of Neuromuscular Diseases ·(unknown), (unknown), (unknown), (unknown), Hoda Abdel‐Hamid, Barry J. Byrne, Anne M. Connolly, Peter Heydemann, Crystal M. Proud, Perry B. Shieh, Kathryn R. Wagner, A. Dugar, Sourav Santra, James Signorovitch, Nathalie Goemans, Craig M. McDonald, Eugenio Mercuri, Jerry R. Mendell	31
4	Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study 2020 ·BMJ Open ·Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Sourav Santra, Nolan Campbell, Pei‐Ran Ho	17
5	Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE 2019 ·BMC Neurology ·Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, (unknown), Sourav Santra, Christophe Hotermans, Lily Lee	40
6	Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis 2018 ·CNS Drugs ·Mark Gudesblatt, (unknown), (unknown), (unknown), Lori Fafard, Jeffrey Wilken, (unknown), Marijean Buhse, Sourav Santra, Christophe Hotermans, Lily Lee	15
7	Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006) 2017 ·Neurology ·Àlex Rovira, Aaron Boster, Giancarlo Comi, Regina Berkovich, Daniel Pelletier, Sven Schippling, Anthony Traboulsee, Christopher LaGanke, David Margolin, Sourav Santra, Douglas L. Arnold	1
8	Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. 2015 ·Journal of Clinical Oncology ·Adi Diab, Alison Martin, Lauren Simpson, Alain P. Algazi, (unknown), Daewon Kim, Sourav Santra, (unknown), (unknown), (unknown), Michael A. Davies, Shama Buch, Kevin Kim, Adil Daud	8
9	Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan 2012 ·Clinical Rheumatology ·Tomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi, Kenichi Yamaguchi, Yasuhiko Itoh, Toshinao Kawai, Naomi Iwata, Takuji Murata, Ikuo Okafuji, Mari Miyoshi, (unknown), Yoshifumi Kawano, Noriko Kinjo, Masaaki Mori, Neelufar Mozaffarian, H. Küpper, Sourav Santra, (unknown), Shinichi Kawai, Shumpei Yokota	58
10	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study 2012 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Roy Fleischmann, Paul Emery, H. Küpper, Laura Redden, B. Guérette, Sourav Santra, Josef S Smolen	181
11	SAT0134 Biologic free disease control (BFDC) in early RA: Predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ada plus methotrexate (MTX) – data from the optima study 2012 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Paul Emery, R. Fleischmann, Ronald van Vollenhoven, S. Florentinus, Sourav Santra, H. Küpper, Arthur Kavanaugh	3
12	FRI0337 Safety and efficacy of adalimumab in children with active polyarticular juvenile idiopathic arthritis aged 2 to <4 years or ≥4 years weighing <15 kg 2012 ·Annals of the Rheumatic Diseases ·D. Kingsbury, Pierre Quartier, Sourav Santra, H. Küpper, Neelufar Mozaffarian	2
13	FRI0171 Achieving long-term comprehensive disease control with adalimumab and methotrexate in patients with early rheumatoid arthritis in the optima study 2012 ·Annals of the Rheumatic Diseases ·Paul Emery, Josef S Smolen, R. Fleischmann, Ronald van Vollenhoven, S. Florentinus, Sourav Santra, H. Küpper, Laura Redden, Arthur Kavanaugh	6
14	SAT0122 Efficacy of addition, or continuation, of adalimumab in patients who did not achieve stable low disease activity with methotrexate or adalimumab plus methotrexate in the optima study 2012 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh, R. Fleischmann, Paul Emery, Ronald van Vollenhoven, S. Florentinus, James W. Shaw, Sourav Santra, H. Küpper, Laura Redden, Josef S Smolen	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact